UroGen Pharma (URGN) Scheduled to Post Earnings on Tuesday

UroGen Pharma (NASDAQ:URGNGet Rating) is scheduled to be announcing its earnings results before the market opens on Tuesday, May 10th. Analysts expect the company to announce earnings of ($1.36) per share for the quarter.

UroGen Pharma (NASDAQ:URGNGet Rating) last announced its quarterly earnings results on Monday, March 21st. The company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.09). The company had revenue of $16.17 million during the quarter, compared to the consensus estimate of $16.15 million. UroGen Pharma had a negative net margin of 230.67% and a negative return on equity of 256.66%. On average, analysts expect UroGen Pharma to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

NASDAQ:URGN traded down $0.14 during mid-day trading on Wednesday, hitting $6.61. 156 shares of the stock traded hands, compared to its average volume of 138,968. UroGen Pharma has a 52 week low of $5.61 and a 52 week high of $19.82. The firm’s 50 day moving average is $7.83 and its two-hundred day moving average is $9.95.

URGN has been the subject of several recent analyst reports. Berenberg Bank started coverage on shares of UroGen Pharma in a research note on Wednesday, April 27th. They set a “buy” rating and a $20.00 price objective for the company. HC Wainwright cut their price objective on shares of UroGen Pharma from $34.00 to $26.00 in a research note on Tuesday, March 22nd. Zacks Investment Research raised shares of UroGen Pharma from a “sell” rating to a “hold” rating in a report on Saturday. Finally, The Goldman Sachs Group increased their price target on shares of UroGen Pharma from $10.00 to $11.00 and gave the stock a “neutral” rating in a report on Tuesday, March 22nd.

A number of hedge funds have recently modified their holdings of the business. Citigroup Inc. raised its stake in UroGen Pharma by 63.0% during the fourth quarter. Citigroup Inc. now owns 5,612 shares of the company’s stock worth $53,000 after purchasing an additional 2,169 shares during the period. BNP Paribas Arbitrage SA raised its stake in UroGen Pharma by 359.8% during the third quarter. BNP Paribas Arbitrage SA now owns 3,559 shares of the company’s stock worth $60,000 after purchasing an additional 2,785 shares during the period. Bank of America Corp DE raised its stake in shares of UroGen Pharma by 12.9% in the 4th quarter. Bank of America Corp DE now owns 41,262 shares of the company’s stock valued at $392,000 after acquiring an additional 4,719 shares during the period. Millennium Management LLC raised its stake in shares of UroGen Pharma by 7.7% in the 3rd quarter. Millennium Management LLC now owns 68,687 shares of the company’s stock valued at $1,155,000 after acquiring an additional 4,887 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of UroGen Pharma by 9.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 61,334 shares of the company’s stock valued at $1,032,000 after acquiring an additional 5,277 shares during the period.

UroGen Pharma Company Profile (Get Rating)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

Recommended Stories

Earnings History for UroGen Pharma (NASDAQ:URGN)

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.